Broker Biotech

[Broker Biotech @1204ed81]

Proper buzz from Nuvectis Pharma yesterday at the HC Wainwright BioConnect Conference. They’ve said preliminary efficacy data from Study 1b is landing end of July or first few days of August.
About time we got some good news on this one 🇬🇧🚀 $NVCT

[Broker Biotech @1204ed81]

NXP900 doesn’t just kill tumor cells, it may restore immune surveillance.
$NVCT #AACR #AACR2026 https://t.co/llQ8A5heGS

[Broker Biotech @1204ed81]

And the answer was they did not

[Broker Biotech @1204ed81]

Is there any chance that $NVCT submitted a late-breaking abstract to ASCO 2026 ahead of yesterday’s deadline related to the NXP900 clinical trials?

[Ozmosi @OzmosiHealth]

$NVCT Nuvectis announced they will present P1 Non-Small-Cell Lung Cancer results on 2026-04-21 for NXP-900

More Info: https://t.co/BgmglSv5uw

[Broker Biotech @1204ed81]

A very decent analysis about NXP900 development and Nuvectis $NVCT

[HDIN_Research @Ben_hdin]

The $4.2B Biotech Pivot: Why Nuvectis (NVCT) is Going "All-In" on NXP900... https://t.co/H1sr7O2jd7 來自 @YouTube

[Broker Biotech @1204ed81]

NXP900, a first-in-class Src family kinase inhibitor targeting YAP signaling, shows strong anti-tumor activity in vivo and in vitro models of cholangiocarcinoma strengthen the rationale for advancing it into clinical trials for this indication. $NVCT https://t.co/OwJMT5qf81

[Broker Biotech @1204ed81]

Yes/src kinase inhibitor nxp900, currently in clinical development, combines synergistically with fulvestrant against luminal a breast cancer cell lines in vitro and in vivo https://t.co/m3ckL3dct7 $NVCT

[Broker Biotech @1204ed81]

Baldwin Wealth bought $NVCT worth 3million$ in December

[Broker Biotech @1204ed81]

Bullish for $NVCT: Institutional Baldwin Wealth Partners boosted its stake to ~390K shares per latest 13F, signaling confidence in Nuvectis’ pipeline. With NXP900 Phase 1b combo trial underway and analysts at Strong Buy (avg PT ~$15–18 vs ~$8.50), 2026 could be a key year.

[Broker Biotech @1204ed81]

$ABBV says it is not in talks to adquiere $RVMD
https://t.co/86lcXeGSmH